Adverse-Event & Safety Escalation Policy

1. Report promptly through the correct paths

Send an initial business notice to quality@pharmaamericasgroup.com with “URGENT SAFETY EVENT” in the subject and, if known, the order number, product name, catalog number, and lot. Do not include a patient name, date of birth, full address, medical record, photograph, or other direct identifier in ordinary email. Pharma Americas will identify an appropriate follow-up method if additional sensitive information is necessary.

The reporter, healthcare professional, manufacturer, sponsor, institution, or other responsible party should also use the reporting pathway required for its role. For FDA-regulated human medical products, FDA’s MedWatch program provides voluntary pathways for health professionals, patients, and consumers and identifies industry pathways for mandatory reporters. Reporting to Pharma Americas is not a substitute for reporting to FDA or another authority.

2. Minimum useful case information

• An identifiable reporter and reliable contact method.
• A minimally identifiable or coded affected person where applicable; avoid unnecessary direct identifiers in initial communications.
• The suspect product, product type, catalog number, lot or batch, source, and order information if known.
• A description of the event, exposure, use error, product problem, or outcome and relevant dates.
• Known concomitant products, storage, handling, preparation, route, amount, timing, or other context relevant to authorized reviewers.

3. Preserve evidence and prevent further exposure

Where safe and lawful, segregate remaining product, prevent further use or transfer, maintain appropriate storage, preserve packaging, labels, lot information, photos, records, shipping materials, monitors, preparation records, and relevant samples, and document immediate actions. Do not ship potentially hazardous material or patient specimens to Pharma Americas without written instructions and an approved lawful method.

4. Pharma Americas triage

Pharma Americas will record the notice, identify the relevant product and parties, evaluate apparent seriousness and urgency, preserve the information available, and route the matter to the supplier, manufacturer, labeler, sponsor, client authority, professional reviewer, or regulator as required or appropriate to Pharma Americas’ actual role and applicable law.

Receipt, forwarding, inquiry, assistance, or reporting does not establish causation, defect, regulated status, admission, or liability. Pharma Americas may be unable to provide clinical follow-up and does not direct patient care.

5. Research-use-only exposure or misuse

Any report suggesting human or veterinary administration, compounding, diagnosis, treatment, patient-specific use, or other prohibited use of a research-use-only product is treated as a critical eligibility, safety, and compliance concern. Pharma Americas may suspend account access, hold or cancel unaccepted requests, stop affected coordination, preserve evidence, notify relevant suppliers or authorities where required or appropriate, and require documented corrective action before any relationship is reconsidered.

6. Confidentiality and privacy

Safety information is handled for triage, follow-up, reporting, quality, legal, audit, and defense purposes and may need to be shared with organizations or authorities responsible for the product or event. Reporters should provide the minimum necessary information through the method approved for the case. A business relationship or ordinary website use does not by itself create a HIPAA business associate relationship.

7. Commercial claims are separate

Safety triage is independent of warranty, return, credit, refund, insurance, causation, or liability review. A person should not delay emergency care or required reporting to preserve a commercial claim. Commercial rights and remedies remain governed by the controlling agreement and applicable law.